Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL-M09D1
- Development stage
- Phase 2
- Lead developer
- Biokin Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BL-M09D1 is an **antibody-drug conjugate (ADC)** under development for the treatment of **solid tumors**. It utilizes a small molecule technology platform that features a specific "connector+toxin" approach, similar to that used in BL-B01D1, another ADC developed by the same company. BL-M09D1 is designed to target cancer cells by delivering a cytotoxic payload directly, although its exact molecular targets are not yet fully disclosed in the public domain. The drug is currently in early-phase clinical development, and is being studied predominantly in patients with **locally advanced or metastatic gastrointestinal tumors** and other solid tumors. Development is led by Sichuan Baili Pharmaceutical, a subsidiary of Sichuan Biokin Pharma[1][5][8].
- Brand names
- BL-M09D1BL-M-09D1BL-M 09D1
- Other names
- BL-M09D1BL-M-09D1BL-M 09D1
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on BL-M09D1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL-M09D1.